Get the Stockscreener App
10.32
7.95%
0.76
After Hours:
10.47
0.15
+1.45%
Immix Biopharma Inc stock is traded at $10.32, with a volume of 1.12M.
It is up +7.95% in the last 24 hours and up +20.14% over the past month.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
See More
Previous Close:
$9.56
Open:
$9.56
24h Volume:
1.12M
Relative Volume:
1.43
Market Cap:
$547.08M
Revenue:
-
Net Income/Loss:
$-29.44M
P/E Ratio:
-11.59
EPS:
-0.8906
Net Cash Flow:
$-24.66M
1W Performance:
+19.58%
1M Performance:
+20.14%
6M Performance:
+240.59%
1Y Performance:
+429.23%
1-Day Range:
$9.36
$10.38
1-Week Range:
$8.57
$10.38
52-Week Range:
$1.87
$11.61
Immix Biopharma Inc Stock (IMMX) Company Profile
Name
Immix Biopharma Inc
Sector
Industry
Phone
(888) 958-1084
Address
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
10.32 | 506.80M | 0 | -29.44M | -24.66M | -0.8906 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-26 | Initiated | Morgan Stanley | Overweight |
| Mar-09-26 | Initiated | Citizens | Mkt Outperform |
| Feb-09-26 | Initiated | Mizuho | Outperform |
Immix Biopharma Inc Stock (IMMX) Latest News
Immix Biopharma Finishes NEXICART-2 Trial Enrollment for Amyloidosis - HarianBasis.co
Is Immix Biopharma (IMMX) One of the Best Performing NASDAQ Stocks? - Insider Monkey
We Think Immix Biopharma (NASDAQ:IMMX) Can Afford To Drive Business Growth - Yahoo Finance
5 Best Performing NASDAQ Stocks According to Wall Street Analysts - Insider Monkey
[SCHEDULE 13G/A] Immix Biopharma, Inc. Amended Passive Investment Disclosure - Stock Titan
IMMX SEC FilingsImmix Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Immix rises as Morgan Stanley starts with bullish view on CAR-T therapy - MSN
Immix Biopharma, Inc. (NASDAQ:IMMX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Immix Biopharma (IMMX) price target increased by 11.73% to 18.62 - MSN
IMMX (Immix Biopharma Inc.) posts wider Q4 2025 EPS miss, shares edge higher as investors focus on long-term pipeline.Retail Trader Ideas - Cổng thông tin điện tử tỉnh Lào Cai
IMMX Immix Biopharma Inc. posts wider Q4 2025 loss than expected as its shares gain nearly four percent on positive investor sentiment.Profit Announcement - Cổng thông tin điện tử tỉnh Tây Ninh
Immix Biopharma (IMMX) price target increased by 50.00% to 12.24 - MSN
HC Wainwright & Co. maintains Immix Biopharma (IMMX) buy recommendation - MSN
IMMX Immix Biopharma posts wider than expected Q4 2025 loss, shares edge lower on investor disappointment.Community Trade Ideas - Newser
Immix Biopharma (NASDAQ:IMMX) Trading Down 4.6%Time to Sell? - MarketBeat
We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely - 富途牛牛
Moving Averages: Should I trade or invest in Immix Biopharma IncWall Street Watch & Precise Swing Trade Alerts - baoquankhu1.vn
IMMX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bear Alert: Is Immix Biopharma Inc in a bullish channel2026 Analyst Calls & Weekly High Conviction Ideas - baoquankhu1.vn
Guidance Update: Is Immix Biopharma Inc stock a buy or sell2026 Bull vs Bear & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Does inflation impact Immix Biopharma (IMMX) Stock | Price at $9.19, Down 5.79%Swing Entry Points - Newser
Immix Biopharma to Participate in Jefferies Global Healthcare Conference - National Today
Immix Biopharma to Host Investor Meetings at Jefferies Global Healthcare Conference 2026 - Quiver Quantitative
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
Immix Biopharma lines up investor meetings at Jefferies event - Stock Titan
Is Immix Biopharma (IMMX) Stock Ready to Move | Price at $9.09, Up 5.82%Stock Surge - Xã Thanh Hà
Immix Biopharma (IMMX) seeks approval of board slate, auditor and reviews 2025 executive pay - Stock Titan
Earnings Recap: Is Immix Biopharma Inc benefiting from innovation trendsNew Guidance & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Is Immix Biopharma (IMMX) Stock showing reversal signs | Price at $9.26, Down 5.03%Top Analyst Picks - Cổng thông tin điện tử Tỉnh Sơn La
Immix Biopharma, Inc. (NASDAQ:IMMX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Immix Biopharma Stock Price Forecast. Should You Buy IMMX? - stockinvest.us
Citizens Initiates Coverage of Immix Biopharma (IMMX) with Market Outperform Recommendation - MSN
IMMX PE Ratio & Valuation, Is IMMX Overvalued - Intellectia AI
Immix Biopharma ― NEXICART-2 の進展で勢いが増す - Smartkarma
Weekly Earnings: Is Immix Biopharma Inc stock a buy or sell2026 Chart Watch & Daily Entry Point Alerts - baoquankhu1.vn
Bear Alert: Is Immix Biopharma Inc benefiting from innovation trends2026 WrapUp & Smart Swing Trading Techniques - baoquankhu1.vn
Citizens reiterates Immix Biopharma stock rating on trial enrollment By Investing.com - Investing.com South Africa
Citizens reiterates Immix Biopharma stock rating on trial enrollment - Investing.com
Immix Biopharma completes enrollment in AL amyloidosis trial By Investing.com - Investing.com South Africa
Immix Biopharma Inc Stock (IMMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):